BridgeBio Surges Past 50-Day MA Amid Pfizer Patent Expiration Fallout

BridgeBio Pharma (BRDG) surged past its 50-day moving average in early March 2026, marking a notable technical breakout amid broader sector volatility. The momentum followed the expiration of Pfizer’s (PFE) patent on an anticoagulant drug used in over 1.2 million patients annually, paving the way for generic competition. This development intensified pressure on drug pricing and reshaped competitive dynamics across the biopharmaceutical landscape. The patent expiration, which took effect on February 28, 2026, led to a 17% immediate price drop for the brand-name drug in the U.S. market, according to real-world pharmacy data. In response, BridgeBio accelerated its development of a biosimilar candidate, which entered Phase 3 trials in early March with projected approval by Q3 2027. The company also announced a strategic licensing agreement with a European generics manufacturer, expanding its reach into key markets. BRDG’s stock rose 12.4% over the week following the patent expiry, closing at $48.70 on March 10, well above its 50-day average of $43.15. The gain outpaced the S&P 500 Health Care Sector ETF (XLV), which rose 2.3% during the same period. Analysts noted that BridgeBio’s diversified pipeline, including three Phase 3 programs, positions it to capture market share in post-patent markets more effectively than peers with narrower portfolios. The broader implications extend beyond BRDG and PFE. The event signals a growing trend in the healthcare sector where patent cliffs drive rapid shifts in market share and investor sentiment. Companies with robust biosimilar pipelines, strong regulatory strategy, and access to distribution networks are gaining favor, particularly in high-volume therapeutic areas like cardiology and oncology.